ONCONETIX
LIVE

Serial Number

98267927

Owner

ONCONETIX, INC.

Attorney

Danielle Cohen, Esq.

Filing Date

Nov 13, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ONCONETIX Trademark

Serial Number: 98267927

ONCONETIX is a trademark filed by ONCONETIX, INC. on November 13, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

ONCONETIX, INC. (4 trademarks)

201 E. FIFTH STREET
CINCINNATI, OH 45202

Entity Type: 03

BLUE WATER BIOTECH, INC. (5 trademarks)

SUITE 1900
CINCINNATI, OH 45202

Entity Type: 03

Trademark Details

Filing Date

November 13, 2023

Registration Date

Not Registered

Published for Opposition

August 6, 2024

Goods & Services

Biobanking services, namely, human and animal organ and tissue bank services; Medical digital pathology services for diagnostic or treatment purposes of human and animal tumors; Medical imaging services for cellular systems for the characterization of human and animal tumors

Downloadable medical computer software platforms containing diagnostic algorithms and decision-making computation to support screening, diagnosing, monitoring and treatment modalities of diseases; downloadable medical computer software platforms for aiding in decision-making in clinical and after-regulatory approval of therapeutics and diagnostics; downloadable medical computer software platforms for managing and maintaining pre-clinical trials, clinical trials and assessments of patient's tumors in their staging and treatment

Medical apparatus for personalized medical therapeutics, namely, infusion and injection devices for administering therapeutic drugs of various types, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics, into the human body utilizing both in-vivo and in-vitro, gene or cellular therapy methods

Pharmaceutical preparations for the treatment of cancer featuring small molecules, biopharmaceuticals, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics; Pharmaceutical preparations for the treatment of cancer for use in cellular therapies, gene therapies, N - 1 personalized drug therapies, and CAR T-cell therapy; Pharmaceutical preparations for the treatment of cancer derived from CRISPR-Cas9 and CAR T-Cell; Vaccine preparations; Antibodies for medical purposes, namely, monoclonal antibodies and bi-specific antibodies; Medical diagnostic reagents and diagnostic preparations for use in-vitro, in-vivo, cell-based assays, cell culture processes, laboratory-developed tests (LDTs), cell-based imagining, genomics, gene-based expression assays, proteomics, protein-based expression assays, immunohistochemistry (IHC), drug sensitivity and treatment diagnostics

Medical research services in personalized medicine, patient treatment, therapeutics and diagnostics

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2026 EXRA
SOU EXTENSION 3 GRANTED
Mar 25, 2026 EX3G
SOU EXTENSION 3 FILED
Mar 25, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 25, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 25, 2025 EXRA
SOU EXTENSION 2 GRANTED
Sep 25, 2025 EX2G
SOU EXTENSION 2 FILED
Sep 25, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 25, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 1, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 31, 2025 EX1G
SOU EXTENSION 1 FILED
Mar 31, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 31, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 1, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 6, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 6, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 17, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 1, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 28, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 28, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 28, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 24, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 20, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 24, 2024 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 16, 2023 NWOS